Envestnet Asset Management Inc. Grows Stake in United Therapeutics Co. (NASDAQ:UTHR)

Envestnet Asset Management Inc. raised its stake in United Therapeutics Co. (NASDAQ:UTHR) by 12.7% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 48,981 shares of the biotechnology company’s stock after acquiring an additional 5,531 shares during the quarter. Envestnet Asset Management Inc. owned approximately 0.11% of United Therapeutics worth $15,603,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently modified their holdings of UTHR. ClariVest Asset Management LLC lifted its stake in shares of United Therapeutics by 120.0% during the 2nd quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company’s stock valued at $25,000 after buying an additional 42 shares in the last quarter. V Square Quantitative Management LLC purchased a new stake in shares of United Therapeutics during the 2nd quarter valued at approximately $30,000. Rise Advisors LLC purchased a new stake in shares of United Therapeutics during the 1st quarter valued at approximately $32,000. Innealta Capital LLC purchased a new stake in shares of United Therapeutics during the 2nd quarter valued at approximately $33,000. Finally, Benjamin F. Edwards & Company Inc. lifted its stake in shares of United Therapeutics by 63.6% during the 1st quarter. Benjamin F. Edwards & Company Inc. now owns 301 shares of the biotechnology company’s stock valued at $69,000 after buying an additional 117 shares in the last quarter. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at United Therapeutics

In related news, CFO James Edgemond sold 7,785 shares of the stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $362.37, for a total transaction of $2,821,050.45. Following the transaction, the chief financial officer now owns 2,615 shares of the company’s stock, valued at approximately $947,597.55. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other United Therapeutics news, CEO Martine A. Rothblatt sold 3,600 shares of the firm’s stock in a transaction on Thursday, June 27th. The shares were sold at an average price of $316.62, for a total value of $1,139,832.00. Following the sale, the chief executive officer now owns 130 shares of the company’s stock, valued at approximately $41,160.60. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO James Edgemond sold 7,785 shares of the firm’s stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $362.37, for a total transaction of $2,821,050.45. Following the completion of the sale, the chief financial officer now directly owns 2,615 shares in the company, valued at approximately $947,597.55. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 114,852 shares of company stock valued at $38,079,259. Insiders own 12.50% of the company’s stock.

United Therapeutics Price Performance

Shares of NASDAQ:UTHR opened at $357.87 on Wednesday. The company’s fifty day moving average price is $340.35 and its 200-day moving average price is $293.69. The firm has a market capitalization of $15.87 billion, a price-to-earnings ratio of 16.92, a PEG ratio of 1.25 and a beta of 0.57. United Therapeutics Co. has a one year low of $208.62 and a one year high of $366.08. The company has a debt-to-equity ratio of 0.02, a current ratio of 4.35 and a quick ratio of 4.18.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, July 31st. The biotechnology company reported $5.85 EPS for the quarter, missing analysts’ consensus estimates of $6.33 by ($0.48). United Therapeutics had a return on equity of 18.82% and a net margin of 40.87%. The company had revenue of $714.90 million during the quarter, compared to the consensus estimate of $691.87 million. During the same period in the previous year, the company earned $5.24 EPS. United Therapeutics’s quarterly revenue was up 19.8% on a year-over-year basis. On average, equities research analysts anticipate that United Therapeutics Co. will post 24.86 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts recently commented on UTHR shares. Bank of America dropped their price target on shares of United Therapeutics from $303.00 to $280.00 and set an “underperform” rating on the stock in a research note on Thursday, August 1st. Jefferies Financial Group increased their target price on shares of United Therapeutics from $315.00 to $432.00 and gave the stock a “buy” rating in a research note on Monday. UBS Group increased their target price on shares of United Therapeutics from $300.00 to $370.00 and gave the stock a “buy” rating in a research note on Monday, July 8th. TD Cowen increased their target price on shares of United Therapeutics from $270.00 to $350.00 and gave the stock a “buy” rating in a research note on Thursday, July 11th. Finally, HC Wainwright reiterated a “buy” rating and issued a $400.00 target price on shares of United Therapeutics in a research note on Thursday, August 1st. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and eleven have assigned a buy rating to the stock. According to MarketBeat.com, United Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $357.17.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.